SILO Point Capital Inc

Uppercut Brands Launches New Direct-to-Consumer Online Store

Uppercut Brands Launches New Direct-to-Consumer Online Store

New Web Presence to Expand Product Offering & Margins

NEW YORK , Feb. 07, 2020 (GLOBE NEWSWIRE) -- Uppercut Brands (OTC PINK: UCUT ) an urban fashion and lifestyle brand, is pleased to announce that its first branded line, “No Found Identification,” has updated its online store with all-new branded and limited edition apparel. The online store is located at . The NFID streetwear collection includes hand lettered designs and custom printed artwork. 

NO FOUND IDENTIFICATION (NFID) is a division of Upper Cut Brands, Inc. The clothing crafted by NFID is inspired by the heart and soul of the country that raised us. 

“NFID is born from the hip-hop, punk rock, and hard work that defined our youth and shaped our destiny. Today, that identity lives on in what we create for a vast market of people who want to cloak themselves in a combination of nostalgia and a desire to keep these important cultural staples moving forward,” stated Eric Weisblum, CEO, Uppercut Brands.  “It’s made for the rebellious at heart… the makers, the doers, and those who refuse to be defined. It’s workwear for the creative – durable, authentic, and designed to wear the markings and memories of individual journeys.

“Our commitment to the consumer is simple: to design the highest quality, most durable workwear available, so it can become a canvas for your life.”

“It is very exciting to launch our ecommerce site and to bring our first apparel to market. The company plans to introduce new, limited, and original designed products throughout the year working with artists and collaborations across many different cultures,” added Weisblum. “And by commercializing our creations direct-to-consumer we can widen margins that will inevitably be imperative to Wall Street and our valued investors.”

For more information regarding NFID please visit 

Safe Harbor and Forward-Looking Statements

This news release contains statements that involve expectations, plans or intentions (such as those relating to future expansion or financial results) and other factors discussed from time to time in the Company's OTC Markets filings. These statements are forward-looking and are subject to risks and uncertainties, so actual results may vary materially. You can identify these forward-looking statements by words such as "may," "should," "expect," "anticipate," "believe," "estimate," "intend," "plan" and other similar expressions. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors not within the control of the company. The company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

Contact:         

EN
07/02/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Point Capital Inc

 PRESS RELEASE

Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on...

Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation Parkinson's disease, bipolar disorder, and chronic pain targeted in study Study aims to support psilocybin as a potential therapeutic for inflammatory disorders ENGLEWOOD CLIFFS, NJ, Jan. 10, 2023 (GLOBE NEWSWIRE) --   (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced a progress update on its sponsored research study with the University of California, San Francisco (UCSF)...

 PRESS RELEASE

Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis

Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis SPU-21 effective in controlling arthritis progression.  SPU-21 Demonstrates Positive Data in Arthritis Suppression using Silo’s Novel Joint Homing Peptide  ENGLEWOOD CLIFFS, NJ, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of...

 PRESS RELEASE

Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeli...

Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine ENGLEWOOD CLIFFS, NJ, Dec. 01, 2022 (GLOBE NEWSWIRE) --  Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today issued a letter to shareholders highlighting the Company’s progress and potential for its portfolio of novel, IP-protected technologies and assets developed in collaboration with world-class medical research partners. The ...

 PRESS RELEASE

Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tis...

Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue Initial data from study expected in first quarter 2023 ENGLEWOOD CLIFFS, NJ, Nov. 21, 2022 (GLOBE NEWSWIRE) --   (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced its plans to initiate a pilot study of its novel joint homing peptides targeting rheumatoid arthritis (RA), designated as SPU-21, in human synovial tissue surrounding joints and tendons. The three-month study will assess the binding affinit...

 PRESS RELEASE

Silo Pharma Achieves New Milestone for SP-26 Therapeutic -Initiates IN...

Silo Pharma Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation ENGLEWOOD CLIFFS, NJ, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced initial dosing in its IND-enabling study of SP-26, its novel time-released, topical formulation of ketamine. The objective of this safety evaluation study, conducted by Experimur, a Frontage Company, is to evaluate the tolerabilit...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch